Work Group Submits Comments to CMS on Sovaldi, Breakthrough Therapy Designation Medications

The Medicaid Work Group sent a comment letter to the Centers for Medicare & Medicaid Services on the introduction of Sovaldi and other new  Breakthrough Therapy Designation medications and their potential impact on Medicaid costs.